Atherosclerosis, a disease characterized by the accumulation of lipids and inflammatory cells in the arterial wall, is a ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Peptides have emerged as a fascinating class of biomolecules with multifaceted roles across biological systems. Vesugen, a ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

A dual-responsive hydrogel offers a breakthrough in osteoarthritis treatment by inhibiting neurovascularization and reducing ...

Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.